I. Aaberge

发表

Virulence of Streptococcus pneumoniae in mice: a standardized method for preparation and frozen storage of the experimental bacterial inoculum.

M. Løvik, I. Aaberge, J. Eng, 1995, Microbial pathogenesis.

Prenatal exposure to polychlorinated biphenyls and dioxins from the maternal diet may be associated with immunosuppressive effects that persist into early childhood.

H. Knutsen, H. Meltzer, H. van Loveren, 2013, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

Indirect effect of conjugate pneumococcal vaccination in a 2+1 dose schedule.

D. Caugant, I. Aaberge, E. Høiby, 2010, Vaccine.

Pectic Polysaccharides Isolated from Malian Medicinal Plants Protect against Streptococcus pneumoniae in a Mouse Pneumococcal Infection Model

B. Paulsen, D. Diallo, I. Aaberge, 2013, Scandinavian journal of immunology.

Rapid spread in Norway of an erythromycin-resistant pneumococcal clone, despite low usage of macrolides.

D. Caugant, I. Aaberge, P. Littauer, 2007, Microbial drug resistance.

Immune activation and HIV-specific T cell responses are modulated by a cyclooxygenase-2 inhibitor in untreated HIV-infected individuals: An exploratory clinical trial

K. Taskén, P. Sandset, T. Ueland, 2017, PloS one.

Pre-natal exposure to perfluoroalkyl substances may be associated with altered vaccine antibody levels and immune-related health outcomes in early childhood

L. S. Haug, C. Thomsen, H. van Loveren, 2013, Journal of immunotoxicology.

A review of the evidence to inform pneumococcal vaccine recommendations for risk groups aged 2 years and older

A. Steens, I. Aaberge, J. Storsaeter, 2014, Epidemiology and Infection.

Human IgE production in hu-PBL-SCID mice injected with birch pollen and diesel exhaust particles.

M. Løvik, I. Aaberge, P. Gaarder, 1998, Toxicology.

Changes in pneumococcal carriage prevalence and factors associated with carriage in Norwegian children, four years after introduction of PCV13

A. Steens, I. Aaberge, D. Vestrheim, 2020, BMC Infectious Diseases.

Streptococcus pyogenes Isolates Causing Severe Infections in Norway in 2006 to 2007: emm Types, Multilocus Sequence Types, and Superantigen Profiles

D. Caugant, R. Meisal, I. Aaberge, 2009, Journal of Clinical Microbiology.

Immunization of Teenagers with a Fifth Dose of Reduced DTaP-IPV Induces High Levels of Pertussis Antibodies with a Significant Increase in Opsonophagocytic Activity

I. Aaberge, A. Aase, H. Bakke, 2011, Clinical and Vaccine Immunology.

Preserved function after angioembolisation of splenic injury in children and adolescents: a case control study.

L. Osnes, P. Naess, C. Gaarder, 2014, Injury.

Preserved splenic function after angioembolisation of high grade injury.

J. Dormagen, C. Gaarder, H. E. Heier, 2012, Injury.

SCID-Hu mice immunized with a pneumococcal vaccine produce specific human antibodies and show increased resistance to infection

M. Løvik, I. Aaberge, T. Michaelsen, 1992, Infection and immunity.

Human antibody response to a pneumococcal vaccine in SCID‐PBL‐hu mice and simultaneously vaccinated human cell donors

I. Aaberge, E. Groeng, T. Steinsvik, 1996, Clinical and experimental immunology.

Specific human IgE response after immunization with birch pollen in scid mice transplanted with human peripheral blood mononuclear cells-A model for human allergy?

M. Løvik, I. Aaberge, P. Gaarder, 1994, Toxicology in vitro : an international journal published in association with BIBRA.

Standardization and validation of assays determining cellular immune responses against influenza.

F. Oftung, S. van der Werf, Wai Ming Liu, 2010, Vaccine.

The concept of "tailor-made", protein-based, outer membrane vesicle vaccines against meningococcal disease.

R. Rappuoli, D. Caugant, E. Rosenqvist, 2005, Vaccine.

Human antibody responses to pneumococcal surface protein A and capsular polysaccharides during acute and convalescent stages of invasive disease in adult patients.

D. Caugant, I. Aaberge, J. Kolberg, 2014, Pathogens and disease.

Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV)

S. Black, E. Rosenqvist, I. Aaberge, 2013, Human vaccines & immunotherapeutics.

Interlaboratory Standardization of the Measurement of Serum Bactericidal Activity by Using Human Complement against Meningococcal Serogroup B, Strain 44/76-SL, before and after Vaccination with the Norwegian MenBvac Outer Membrane Vesicle Vaccine

E. Rosenqvist, I. Aaberge, J. Findlow, 2005, Clinical Diagnostic Laboratory Immunology.

Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5-year olds in New Zealand.

I. Aaberge, E. Ypma, P. Oster, 2007, Vaccine.

Pherotypes of pneumococcal strains co-existing in healthy children.

D. Caugant, I. Aaberge, P. Gaustad, 2011, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

Sequence Type and emm Type Diversity in Streptococcus pyogenes Isolates Causing Invasive Disease in Norway between 1988 and 2003

D. Caugant, R. Meisal, I. Aaberge, 2008, Journal of Clinical Microbiology.

Experience with pneumococcal conjugate vaccine in Norway

I. Aaberge, 2009, Expert review of vaccines.

New Zealand Epidemic Strain Meningococcal B Outer Membrane Vesicle Vaccine in Children Aged 16–24 Months

K. Mulholland, S. Crengle, D. Lennon, 2007, The Pediatric infectious disease journal.

Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease.

E. Rosenqvist, I. Aaberge, E. Høiby, 2003, Vaccine.

Decline in Early Childhood Respiratory Tract Infections in the Norwegian Mother and Child Cohort Study After Introduction of Pneumococcal Conjugate Vaccination

S. London, P. Nafstad, H. Stigum, 2012, The Pediatric infectious disease journal.

Pneumococcal conjugate vaccines in children

I. Aaberge, 2012 .

Anti-pertussis antibody kinetics following DTaP-IPV booster vaccination in Norwegian children 7-8 years of age.

T. Leegaard, M. Steinbakk, G. Berbers, 2014, Vaccine.

Pneumococcal Vaccine in the Elderly

I. Aaberge, 2005, Drugs & aging.

Intranasal Immunization with Heat-InactivatedStreptococcus pneumoniae Protects Mice against Systemic Pneumococcal Infection

M. Løvik, I. Aaberge, B. Haneberg, 1999, Infection and Immunity.

IgM and IgG response to pneumococcal polysaccharide vaccine in normal individuals and individuals splenectomized due to trauma.

K. Giercksky, H. E. Heier, I. Aaberge, 2009, Acta pathologica, microbiologica, et immunologica Scandinavica. Section C, Immunology.

Immunogenicity of Fractional Doses of Tetravalent A/C/Y/W135 Meningococcal Polysaccharide Vaccine: Results from a Randomized Non-Inferiority Controlled Trial in Uganda

L. Pinoges, D. Caugant, P. Guérin, 2008, PLoS neglected tropical diseases.

Immunogenicity and Safety of a Combination of Two Serogroup B Meningococcal Outer Membrane Vesicle Vaccines

E. Rosenqvist, I. Aaberge, A. Aase, 2007, Clinical and Vaccine Immunology.

Immunogenicity and Safety of a Combination of Two Serogroup B 1

I. Aaberge, A. Aase, H. Nøkleby, 2007 .

Persisting Immune Responses Indicating Long-Term Protection after Booster Dose with Meningococcal Group B Outer Membrane Vesicle Vaccine

E. Rosenqvist, I. Aaberge, H. Nøkleby, 2006, Clinical and Vaccine Immunology.

Pharyngeal carriage of Neisseria meningitidis in 2-19-year-old individuals in Uganda.

D. Caugant, P. Guérin, J. Røttingen, 2006, Transactions of the Royal Society of Tropical Medicine and Hygiene.

Human Opsonins Induced during Meningococcal Disease Recognize Outer Membrane Proteins PorA and PorB

A. Halstensen, I. Aaberge, T. Michaelsen, 1999, Infection and Immunity.

Enhancement of Streptococcus pneumoniae serotype 6B infection in mice after passive immunization with human serum.

M. Løvik, I. Aaberge, B. Hvalbye, 1996, Microbial pathogenesis.

Safety and immunogenicity of New Zealand strain meningococcal serogroup B OMV vaccine in healthy adults: beginning of epidemic control.

K. Rasanathan, K. Mulholland, D. Lennon, 2006, Vaccine.

A ‘tailor made’ vaccine trialled as part of public health response to group B meningococcal epidemic in New Zealand

R. Rappuoli, K. Nord, D. Lennon, 2003 .

Immunisation schedules for non-replicating nasal vaccines can be made simple by allowing time for development of immunological memory.

I. Aaberge, B. Haneberg, E. Høiby, 2004, Vaccine.

Influence of Intravenous Anesthesia on Mucosal and Systemic Antibody Responses to Nasal Vaccines

I. Aaberge, B. Haneberg, E. Høiby, 2002, Infection and Immunity.

Meningococcal Outer Membrane Vesicle Vaccine Given Intranasally Can Induce Immunological Memory and Booster Responses without Evidence of Tolerance

F. Oftung, I. Aaberge, B. Haneberg, 2001, Infection and Immunity.

Combined Administration of Meningococcal Serogroup B Outer Membrane Vesicle Vaccine and Conjugated Serogroup C Vaccine Indicated for Prevention of Meningococcal Disease Is Safe and Immunogenic

I. Aaberge, E. Høiby, E. Ypma, 2005, Clinical Diagnostic Laboratory Immunology.

Proceedings of the Meningococcal Vaccine Strategy World Health Organization satellite meeting, 10 March 2004, Auckland, New Zealand.

D. Lennon, I. Aaberge, S. Reid, 2004, The New Zealand medical journal.

Postvaccination Increase in Serotype 19A Pneumococcal Disease in Norway Is Driven by Expansion of Penicillin-Susceptible Strains of the ST199 Complex

D. Caugant, M. Steinbakk, I. Aaberge, 2012, Clinical and Vaccine Immunology.

Carriage of Streptococcus pneumoniae in healthy Norwegian children attending day-care centres

D. Caugant, I. Aaberge, E. Høiby, 2006, European Journal of Clinical Microbiology and Infectious Diseases.

Cancer patients undergoing chemotherapy show adequate serological response to vaccinations against influenza virus and Streptococcus pneumoniae

I. Aaberge, H. H. Samdal, A. Husebekk, 2002, Medical oncology.

Opsonophagocytic Activity and Other Serological Indications of Bordetella pertussis Infection in Military Recruits in Norway

I. Aaberge, B. Berdal, A. Aase, 2007, Clinical and Vaccine Immunology.

IgG Subclass Antibody Responses to Pneumococcal Polysaccharide Vaccine in Splenectomized, Otherwise Normal, Individuals

H. E. Heier, I. Aaberge, T. Michaelsen, 1990, Scandinavian journal of immunology.

IgA response to pneumococcal polysaccharide vaccine in individuals splenectomized because of trauma.

H. E. Heier, I. Aaberge, E. Groeng, 2009, Acta pathologica, microbiologica, et immunologica Scandinavica. Section C, Immunology.

An Exploratory Trial of Cyclooxygenase Type 2 Inhibitor in HIV-1 Infection: Downregulated Immune Activation and Improved T Cell-Dependent Vaccine Responses

E. Aandahl, K. Taskén, P. Sandset, 2011, Journal of Virology.

Multilaboratory Comparison of Pneumococcal Multiplex Immunoassays Used in Immunosurveillance of Streptococcus pneumoniae across Europe

B. D. de Jong, K. Ljungberg, H. Prince, 2019, mSphere.

Protective Effect of Plantago major L. Pectin Polysaccharide against Systemic Streptococcus pneumoniae Infection in Mice

B. Paulsen, I. Aaberge, T. Michaelsen, 2000, Scandinavian journal of immunology.

Novel Pyrogen Tests Based on the Human Fever Reaction

Thomas Hartung, Sandra Coecke, Matthias Fischer, 2001, Alternatives to laboratory animals : ATLA.

International validation of novel pyrogen tests based on human monocytoid cells.

Sebastian Hoffmann, Thomas Hartung, Sandra Coecke, 2005, Journal of immunological methods.

Laboratory Methods for Detection of Infectious Agents and Serological Response in Humans With Tick-Borne Infections: A Systematic Review of Evaluations Based on Clinical Patient Samples

S. Flottorp, P. Forsberg, I. Aaberge, 2021, Frontiers in Public Health.

Hypogammaglobulinemia and Risk of Exacerbation and Mortality in Patients with COPD

J. Kongerud, T. Rustøen, I. Aaberge, 2020, International journal of chronic obstructive pulmonary disease.

The Antibody Response to Secondary Immunization with Pneumococcal Polysaccharides in Mice

I. Aaberge, M. Løvik, 1995, Scandinavian journal of immunology.

Antibody Response to Pneumococcal Polysaccharide Vaccine in Young, Adult and Old Mice

I. Aaberge, R. North, E. Groeng, 1993, Scandinavian journal of immunology.

The antibody response after immunization with pneumococcal polysaccharide vaccine in splenectomized mice: the effect of re‐immunization with pneumococcal antigens

I. Aaberge, M. Løvik, 1996, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

Long-term effect of pneumococcal polysaccharide vaccination on serum IgM and IgG antibody levels in individuals splenectomized for trauma.

H. E. Heier, I. Aaberge, 2009, Acta pathologica, microbiologica, et immunologica Scandinavica. Section C, Immunology.

Validate or falsify: Lessons learned from a microscopy method claimed to be useful for detecting Borrelia and Babesia organisms in human blood

P. Wilhelmsson, I. Aaberge, P. Lindgren, 2016, Infectious diseases.

Tetanus after a minor injury leading to death in a previously non-immunized, elderly, Norwegian woman

I. Aaberge, O. Dunlop, B. Brandsæter, 2015, IDCases.

Phase II meningococcal B vesicle vaccine trial in New Zealand infants

K. Mulholland, S. Crengle, D. Lennon, 2008, Archives of Disease in Childhood.

What should be done in cases of suspected tick-borne disease?

I. Aaberge, A. Aase, H. Reiso, 2021, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.

Are the current notification criteria for Lyme borreliosis in Norway suitable? Results of an evaluation of Lyme borreliosis surveillance in Norway, 1995–2013

Richard A. White, P. Stefanoff, K. Nygård, 2016, BMC Public Health.

Geographical differences in seroprevalence of Borrelia burgdorferi antibodies in Norway, 2011-2013.

Richard A. White, I. Aaberge, A. Aase, 2016, Ticks and tick-borne diseases.

Effectiveness of a 2+1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway.

D. Caugant, I. Aaberge, E. Høiby, 2008, Vaccine.

SARS-CoV-2 antibody persistence after five and twelve months: A cohort study from South-Eastern Norway

J. Vandenbroucke, L. Diep, H. Kersten, 2022, medRxiv.

Characterization of the extent of a large outbreak of Legionnaires’ disease by serological assays

I. Aaberge, E. Ragnhildstveit, A. Kanestrøm, 2015, BMC Infectious Diseases.

The Immune Response to Pneumococcal Polysaccharide Vaccine in Zinc‐Depleted Mice *

A. Maage, E. Ulvestad, I. Aaberge, 2003, Scandinavian journal of immunology.

Tracking airborne Legionella and Legionella pneumophila at a biological treatment plant.

G. Skogan, J. Blatny, D. Caugant, 2008, Environmental science & technology.

An outbreak of legionnaires disease caused by long-distance spread from an industrial air scrubber in Sarpsborg, Norway.

Preben Aavitsland, D. Caugant, K. Nygård, 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Halogenated organic compounds and the human immune system: preliminary report on a study in hobby fishermen.

G. Becher, M. Løvik, J. Alexander, 1996, Archives of toxicology. Supplement. = Archiv fur Toxikologie. Supplement.

COPD_A_236656 799..807

J. Kongerud, T. Rustøen, I. Aaberge, 2020 .

Etiology of Pneumonia in a Pediatric Population with High Pneumococcal Vaccine Coverage: A Prospective Study

T. Leegaard, B. Nakstad, I. Aaberge, 2016, The Pediatric infectious disease journal.

Protective effect of beta-glucan against systemic Streptococcus pneumoniae infection in mice.

N. Ohno, M. Løvik, I. Aaberge, 2000, FEMS immunology and medical microbiology.

Protective e¡ect of L-glucan against systemic Streptococcus pneumoniae infection in mice

N. Ohno, I. Aaberge, M. Lövik, 2000 .

Impact of a Pneumococcal Conjugate Vaccination Program on Carriage among Children in Norway

D. Caugant, I. Aaberge, E. Høiby, 2010, Clinical and Vaccine Immunology.

Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.

A. Steens, I. Aaberge, D. Vestrheim, 2013, Vaccine.

Decreased Carriage and Genetic Shifts in the Streptococcus pneumoniae Population After Changing the Seven-valent to the Thirteen-valent Pneumococcal Vaccine in Norway

A. Steens, D. Caugant, I. Aaberge, 2015, The Pediatric infectious disease journal.

Phenotypic and Genotypic Characterization of Streptococcus pneumoniae Strains Colonizing Children Attending Day-Care Centers in Norway

D. Caugant, I. Aaberge, E. Høiby, 2008, Journal of Clinical Microbiology.

Predictive Value of Immunologic Parameters and HIV RNA in Relation to Humoral Pneumococcal Polysaccharide Vaccine Responses in Patients with HIV Infection

S. Frøland, I. Aaberge, D. Kvale, 2002, European Journal of Clinical Microbiology and Infectious Diseases.

Efficacy and safety of a third SARS-CoV-2 vaccination in multiple sclerosis vaccine non-responders

F. Lund-Johansen, G. Nygaard, H. Harbo, 2021, medRxiv.

Immunogenicity, Reactogenicity, and Safety of a P1.7b,4 Strain-Specific Serogroup B Meningococcal Vaccine Given to Preteens

K. Rasanathan, J. Hosking, S. Crengle, 2007, Clinical and Vaccine Immunology.

Autoantibodies in individuals splenectomized because of trauma

I. Aaberge, P. Gaarder, 1986, Scandinavian journal of haematology.

Cost-utility analysis of a universal pneumococcal vaccination programme for older adults in Norway

T. Lyngstad, I. Aaberge, L. Nymark, 2022, Human vaccines & immunotherapeutics.

Pneumococcal conjugate vaccine followed by pneumococcal polysaccharide vaccine; immunogenicity in patients with ataxia‐telangiectasia

A. Stray-Pedersen, I. Aaberge, T. Abrahamsen, 2005, Clinical and experimental immunology.

Radioimmunotherapy with iodine-131 tositumomab in patients with low-grade non-Hodgkin's B-cell lymphoma does not induce loss of acquired humoral immunity against common antigens.

M. Kaminski, M. Tuck, I. Aaberge, 2001, Clinical immunology.

Neisseria meningitidis group B correlates of protection and assay standardization--international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005.

R. Rappuoli, M. Caulfield, B. Plikaytis, 2006, Vaccine.

The impact of an early truncating founder ATM mutation on immunoglobulins, specific antibodies and lymphocyte populations in ataxia‐telangiectasia patients and their parents

A. Børresen-Dale, A. Stray-Pedersen, I. Aaberge, 2004, Clinical and experimental immunology.

In vitro and in vivo comparison of transport media for detecting nasopharyngeal carriage of Streptococcus pneumoniae

A. Steens, I. Aaberge, N. Milhano, 2016, PeerJ.